Overall, these data show that the incidence of TP53 disruption in CLL with CK was significantly higher (21-80% of the cases) than in an unselected treatment-naïve CLL population (3-13% of the cases) [22–24, 26, 28–29, 63] or in CLL without CK. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.